VVΔTKΔN1L + IL12

VVΔTKΔN1L + IL12 is a genetically engineered, oncolytic Vaccinia virus (derived from the Lister strain) with deletions in the thymidine kinase (TK) and N1L genes, which has been further "armed" through incorporation of the interleukin-12 (IL-12) gene for local cytokine expression. Deletion of TK and N1L attenuates the virus, increases tumor selectivity, and reduces systemic toxicity; the addition of IL-12 enhances immune-mediated anti-tumor activity. This agent has shown potent and broad-spectrum antitumor effects in preclinical models, including murine models of lung, breast, head & neck, and pancreatic cancers. The mechanism of action involves direct oncolysis, induction of innate and adaptive immune cell infiltration, reprogramming of immune suppressive M2 macrophages toward an antitumor M1 phenotype, reduction of regulatory T cells, and strong anti-angiogenic effects. It is being investigated primarily for use as a neoadjuvant or intratumoral therapy for solid tumors[1][3][5].

Other names

Vaccinia virus ΔTKΔN1L armed with interleukin-12oncolytic Vaccinia virus armed with IL-12